Skip to Main Content

Author Details

David M Nanus
Sandra and Edward Meyer Cancer Center
1983
246
69
PMIDPaper TitleJournal TitlePublished Year
37922438Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591.J Clin Oncol2024
37878135Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.Cancer Causes Control2024
36727061Editorial: Molecular genetics and therapeutic advances in renal carcinoma.Front Oncol2023
38020528Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy.Eur Urol Open Sci2023
37608258Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).BMC Cancer2023
37424145Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.Prostate2023
37217526Novel genetically engineered mouse models for clear cell renal cell carcinoma.Sci Rep2023
36722045NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.Cancer Biol Ther2023
36897758PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.Clin Cancer Res2023
35231161The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.Mol Oncol2022
35726553Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).Mol Carcinog2022
35848798AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer.Elife2022
35896447Nearly All Cancer Survivors Return to Primary Care.J Am Board Fam Med2022
36083412Fatalistic cancer beliefs and self-reported cancer screening behaviors among diverse urban residents.J Behav Med2022
35046520Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.Br J Cancer2022
35274199Cancer and cardiovascular-related perceived risk in a diverse cancer center catchment area.Cancer Causes Control2022
32901370Healthcare fragmentation and cardiovascular risk control among older cancer survivors in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study.J Cancer Surviv2021
33519152Eliciting the Social Determinants of Cancer Prevention and Control in the Catchment of an Urban Cancer Center.Ethn Dis2021
33680970Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.Front Oncol2021
33820782Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.Clin Cancer Res2021
33771885Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.Mol Cancer Res2021
34970493Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma.Front Oncol2021
35083431Highly portable quantitative screening test for prostate-specific antigen at point of care.Curr Res Biotechnol2021
34796255A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin.Am J Clin Exp Urol2021
34099734Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.Nat Commun2021
34286887Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.Oncologist2021
34168263Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage.Commun Biol2021
33465252Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.Prostate2021
32286692Differences in ambulatory care fragmentation between cancer survivors and noncancer controls.Cancer2020
31811682All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).Eur J Haematol2020
31898184NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.Invest New Drugs2020
31865180Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma.Transl Oncol2020
31705765Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.Genes Chromosomes Cancer2020
32091413Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.J Clin Invest2020
33273457Common germline-somatic variant interactions in advanced urothelial cancer.Nat Commun2020
33154984Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.JCO Precis Oncol2020
32662880Hematology and oncology clinical care during the coronavirus disease 2019 pandemic.CA Cancer J Clin2020
32600929Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancer.Urol Oncol2020
32694156A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.Clin Cancer Res2020
32205838Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.Oncogenesis2020
32127465SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.Mol Cancer Ther2020
30301829Expression of AR-V7 and ARv<sup>567es</sup> in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.Clin Cancer Res2019
31815952Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.PLoS One2019
30232224A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.Clin Cancer Res2019
31525487Clinical features of neuroendocrine prostate cancer.Eur J Cancer2019
31265357Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.J Clin Oncol2019
31258968Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent.AMIA Jt Summits Transl Sci Proc2019
31278255Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.Nat Commun2019
31592503Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.JCO Precis Oncol2019
30865916Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.J Natl Compr Canc Netw2019
  • 1 - 50 of 246

Recommended Authors

Alexandra Drakaki
David Geffen School of Medicine at university of california los angeles
Career Start Year 2009
Number of shared co-authors 10
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 4
Thai H Ho
Mayo Clinic Arizona
Career Start Year 2002
Number of shared co-authors 8
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 36
Brian A Costello
The Mayo Clinic
Career Start Year 2001
Number of shared co-authors 2
Randy Caliliw
David Geffen School of Medicine at university of california los angeles
Career Start Year 2000
Number of shared co-authors 0
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 35
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 1
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 47
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 31
Lance C Pagliaro
Mayo Clinic
Career Start Year 1993
Number of shared co-authors 11
Bhaskar Kallakury
Georgetown University
Career Start Year 1993
Number of shared co-authors 3
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 27
Holger Moch
University Hospital Zurich
Career Start Year 1991
Number of shared co-authors 35
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 7
Bernd Wullich
University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)
Career Start Year 1989
Number of shared co-authors 1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 4
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 0
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 3
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1987
Number of shared co-authors 17
David J McConkey
Johns Hopkins School of Medicine
Career Start Year 1986
Number of shared co-authors 14
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 7
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 0
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 10
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 6
Adrian L Harris
University of Oxford
Career Start Year 1981
Number of shared co-authors 10
Fabien Calvo
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 1
Bernard T??tu
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Career Start Year 1979
Number of shared co-authors 5
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 16
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 3

Collaborators

Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 63
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 30
Lorraine J Gudas
Meyer Cancer Center
Co-authored papers 28
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 23
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 23
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 23
Ana M Molina
Englander Institute for Precision Medicine
Co-authored papers 22
Mark A Rubin
University of Bern
Co-authored papers 21
Olivier Elemento
Meyer Cancer Center
Co-authored papers 20
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 15
Victor E Reuter
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Bishoy M Faltas
Sandra and Edward Meyer Cancer Center
Co-authored papers 12
Rohan Bareja
Case Western Reserve University
Co-authored papers 11
Francesca Demichelis
University of Trento
Co-authored papers 11
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 10
Douglas S Scherr
New York-Presbyterian Hospital
Co-authored papers 10
Kenneth Eng
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 9
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 9
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 8
David S Rickman
Meyer Cancer Center
Co-authored papers 8
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Co-authored papers 7
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Co-authored papers 7
Alexandros Sigaras
Columbia University, United States Bureau of Educational and Cultural Affairs Fulbright Program, University of Piraeus, Weill Cornell Medical College, Weill Cornell Medicine
Co-authored papers 7
Maha Hussain
Northwestern University
Co-authored papers 7
Johannes C van der Mijn
New York Presbyterian Hospital
Co-authored papers 7
Theresa Y MacDonald
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 7
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Madhu Mazumdar
Icahn School of Medicine at Mount Sinai
Co-authored papers 6
Kyung Park
New York University Langone Health
Co-authored papers 6
Davide Prandi
University of Trento
Co-authored papers 6
Release 1.2